These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 3724805)

  • 1. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis.
    Slatopolsky E; Weerts C; Lopez-Hilker S; Norwood K; Zink M; Windus D; Delmez J
    N Engl J Med; 1986 Jul; 315(3):157-61. PubMed ID: 3724805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease.
    Salusky IB; Foley J; Nelson P; Goodman WG
    N Engl J Med; 1991 Feb; 324(8):527-31. PubMed ID: 1992306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Calcium carbonate for the treatment of hyperphosphatemia in chronic hemodialysis patients].
    Kiss D; Battegay M; Meier C; Lyrer A
    Schweiz Med Wochenschr; 1990 Mar; 120(9):295-8. PubMed ID: 2315655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RenaGel efficacy in severe secondary hyperparathyroidism.
    Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
    Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
    Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
    Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia.
    Mactier RA; Van Stone J; Cox A; Van Stone M; Twardowski Z
    Clin Nephrol; 1987 Nov; 28(5):222-6. PubMed ID: 3427832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Use of calcium carbonate (CaCO3) as phosphate binder in dialysis patients in long-term follow-up over 3 years].
    Sperschneider H; Günther K; Stein G; Marzoll I; Kirchner E
    Z Urol Nephrol; 1990 Aug; 83(8):449-58. PubMed ID: 2122612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium salts of keto-amino acids, a phosphate binder alternative for patients on CAPD.
    Macia M; Coronel F; Navarro JF; Gallego E; Herrero JA; Méndez ML; Chahin J; García J
    Clin Nephrol; 1997 Sep; 48(3):181-4. PubMed ID: 9342490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcium alginate, an aluminum-free phosphate binder, in patients on CAPD.
    Passlick J; Wilhelm M; Busch T; Grabensee B; Ohnesorge FK
    Clin Nephrol; 1989 Aug; 32(2):96-100. PubMed ID: 2766587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
    Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
    Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of calcium carbonate as a phosphate binder in dialysis patients.
    Hercz G; Kraut JA; Andress DA; Howard N; Roberts C; Shinaberger JH; Sherrard DJ; Coburn JW
    Miner Electrolyte Metab; 1986; 12(5-6):314-9. PubMed ID: 3807829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
    Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ
    Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of long-term treatment with calcium carbonate as a phosphate binder.
    Malberti F; Surian M; Poggio F; Minoia C; Salvadeo A
    Am J Kidney Dis; 1988 Dec; 12(6):487-91. PubMed ID: 3143260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcium acetate used as phosphate binding treatment in uremic hyperphosphatemia.
    Wikström B; Danielson BG; Fellström B
    Adv Perit Dial; 1991; 7():221-4. PubMed ID: 1680430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative phosphate binders in dialysis patients: calcium carbonate.
    Slatopolsky E; Weerts C; Stokes T; Windus D; Delmez J
    Semin Nephrol; 1986 Dec; 6(4 Suppl 1):35-41. PubMed ID: 3602677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphate binders in hyperphosphatemia of chronic renal failure.
    Wasan SM; Godley PJ
    DICP; 1991 Sep; 25(9):942-5. PubMed ID: 1949972
    [No Abstract]   [Full Text] [Related]  

  • 19. Calcium carbonate, an aluminum-free agent for control of hyperphosphatemia, hypocalcemia, and hyperparathyroidism in uremia.
    Fournier A; Moriniere P; Sebert JL; Dkhissi H; Atik A; Leflon P; Renaud H; Gueris J; Gregoire I; Idrissi A
    Kidney Int Suppl; 1986 Feb; 18():S114-9. PubMed ID: 3457987
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of gastric acid suppression with pantoprazole on the efficacy of calcium carbonate as a phosphate binder in haemodialysis patients.
    Cervelli MJ; Shaman A; Meade A; Carroll R; McDonald SP
    Nephrology (Carlton); 2012 Jul; 17(5):458-65. PubMed ID: 22471559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.